Low-field MRI for Breast Cancer Screening

Status Enrolling by invitation

Clinical Trial Summary

This research study wants to learn more about improving the attainable image quality for ultra-low field MRI of the breast using new data acquisition methods(also called MRI pulse sequences) and image reconstruction algorithms. For this pilot study, are testing a new method to image breast cancers at ultra-low magnetic field. The findings from this breast imaging technique will be compared with results obtained from standard mammograms, ultrasounds, MRIs, clinical examinations, and pathology evaluations, when available. The ultra-low field breast MRI performed for this study will be for research purposes and will not be used to guide clinical care.

Clinical Trial Description

This research study is a Feasibility Study, which is the first-time investigators are examining the use of ultra-low field MRI to image breast cancer. The purpose of the study is to develop, test and improve new software techniques for our magnetic resonance imaging (MRI) systems. In developing new, ultra-low field MRI scanners develop sequences and other software algorithms from time to time. This study will enroll both healthy participants and persons with breast cancer. This investigation will also compare these images to standard mammograms, ultrasounds, MRIs, clinical examinations, and pathology evaluations when available. It is expected that about 40 people will take part in this research study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05486520
Study type	Interventional
Source	Massachusetts General Hospital
Contact
Status	Enrolling by invitation
Phase	N/A
Start date	September 1, 2022
Completion date	September 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02378337` - Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality	N/A
Completed	`NCT01953003` - Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer	Phase 3
Not yet recruiting	`NCT01395706` - ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes	Phase 2
Completed	`NCT05159778` - Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA)	Phase 2
Active, not recruiting	`NCT03379428` - Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer	Phase 1/Phase 2
Completed	`NCT02891681` - Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment	N/A
Withdrawn	`NCT03261323` - Breast Reconstruction Following Breast Cancer in Very High Risk Patients	N/A
Recruiting	`NCT04669873` - Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery	N/A
Completed	`NCT02408393` - MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery	Phase 3
Completed	`NCT03289819` - Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC	Phase 2
Completed	`NCT02495363` - Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients
Completed	`NCT03159195` - Ibrance Real World Insights
Completed	`NCT03425656` - Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust) Versus Herceptin® in Breast Cancer	Phase 3
Active, not recruiting	`NCT05033756` - Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO	Phase 2
Not yet recruiting	`NCT01641003` - Isolation and Characterization of Cancer Stem Cells Using iFP Technique	N/A
Active, not recruiting	`NCT05364450` - Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors	N/A
Active, not recruiting	`NCT03435952` - Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT	Phase 1
Active, not recruiting	`NCT02204098` - Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy	Phase 1
Not yet recruiting	`NCT06251544` - TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer	Phase 1
Active, not recruiting	`NCT02187991` - Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer	Phase 2